Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Rapid Initiation of ART

In this on-demand recording of a live webinar, expert faculty review key considerations for rapid initiation of ART. Topics include current recommendations and a discussion of the data to support ART options for rapid initiation.
Jason Halperin, MD, MPH
Jürgen K. Rockstroh, MD
Released: September 29, 2021

In this episode from the series “Key Decisions in HIV Care,” Jason Halperin, MD, MPH, and Jürgen K. Rockstroh, MD, discuss important considerations in the rapid initiation of ART, including guideline recommendations and data supporting recommended ART regimen options for rapid initiation and emerging data for the 2-drug regimen dolutegravir/lamivudine for rapid start from the STAT study. Following their dialogue, the faculty field questions from healthcare professionals.

Information on this Educational Activity

Faculty

Jason Halperin, MD, MPH

Assistant Professor of Medicine
Department of Infectious Diseases
Tulane University
Infectious Disease Physician
CrescentCare
New Orleans, Louisiana

Jason Halperin, MD, MPH, has no relevant conflict of interest to report.
Jürgen K. Rockstroh, MD

Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Galapagos, Gilead Sciences, Merck, and ViiV and fees for non-CME/CE services from Gilead Sciences, Janssen, Merck, Theratechnologies, and ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Commentary from Dr Jason Halperin on the use of 2-drug ART for rapid start, from Clinical Care Options (CCO)

Jason Halperin, MD, MPH Released: November 29, 2021

Expert recap of new data on HIV drug resistance from EACS 2021, from Dr Babafemi Taiwo and Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: November 23, 2021

Clinical Care Options (CCO) expert analysis of new data from EACS 2021, provided by expert HIV faculty

person default Tristan J. Barber, MA, MD, FRCP Released: November 22, 2021

Perspective on the contribution of mental health to the cascade of care in Europe, from Clinical Care Options (CCO) and Dr. Tristan Barber

person default Tristan J. Barber, MA, MD, FRCP Released: November 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue